FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804764624> ?p ?o ?g. }

• W2804764624 endingPage "2701" @default.
• W2804764624 startingPage "2693" @default.
• W2804764624 abstract "Purpose In patients with crizotinib-treated, anaplastic lymphoma kinase gene ( ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC), initial disease progression often occurs in the CNS. We evaluated brigatinib, a next-generation ALK inhibitor, in patients with ALK-positive NSCLC with brain metastases. Patients and Methods Patients with ALK-positive NSCLC received brigatinib (90 to 240 mg total daily) in a phase I/II trial (phI/II; ClinicalTrials.gov identifier: NCT01449461) and in the subsequent randomized phase II trial ALTA (ALK in Lung Cancer Trial of AP26113; ClinicalTrials.gov identifier: NCT02094573; patients in arm A received 90 mg once daily; patients in arm B received 180 mg once daily with 7-day lead-in at 90 mg). Primary end points (systemic objective response rates [ORRs]) were previously reported. Independent review committees assessed intracranial efficacy in patients with baseline brain metastases. Results Most patients with ALK-positive NSCLC had baseline brain metastases (50 of 79 [63%], phI/II; 80 of 112 [71%] and 73 of 110 [66%] in ALTA arms A and B, respectively), many of whom had no prior brain radiotherapy (23 of 50 [46%], phI/II; 32 of 80 [40%], ALTA arm A; 30 of 73 [41%], arm B). All patients, except four in phI/II, had received crizotinib. Among patients with measurable (≥ 10 mm) brain metastases, confirmed intracranial ORR was 53% (eight of 15; 95% CI, 27% to 79%) in phI/II, 46% (12 of 26; 95% CI, 27% to 67%) in ALTA arm A, and 67% (12 of 18; 95% CI, 41% to 87%) in arm B. Intracranial ORRs were similar in subsets without prior radiation or progression postradiation. Among patients with any baseline brain metastases, median intracranial progression-free survival (iPFS) was 14.6 months (95% CI, 12.7 to 36.8 months), phI/II; 15.6 months (95% CI, 9.0 to 18.3 months), ALTA arm A; 18.4 months (95% CI, 12.8 months to not reached), ALTA arm B. Conclusion Brigatinib yielded substantial intracranial responses and durable iPFS in ALK-positive, crizotinib-treated NSCLC, with highest iPFS in patients receiving 180 mg once daily (with lead-in)." @default.
• W2804764624 created "2018-06-01" @default.
• W2804764624 creator A5003670561 @default.
• W2804764624 creator A5007762760 @default.
• W2804764624 creator A5008594172 @default.
• W2804764624 creator A5012226414 @default.
• W2804764624 creator A5014132939 @default.
• W2804764624 creator A5016978421 @default.
• W2804764624 creator A5036466135 @default.
• W2804764624 creator A5038912570 @default.
• W2804764624 creator A5041640815 @default.
• W2804764624 creator A5043983803 @default.
• W2804764624 creator A5055082049 @default.
• W2804764624 creator A5070967174 @default.
• W2804764624 creator A5071783009 @default.
• W2804764624 creator A5073284312 @default.
• W2804764624 creator A5077797768 @default.
• W2804764624 creator A5080311196 @default.
• W2804764624 creator A5082517668 @default.
• W2804764624 creator A5090256464 @default.
• W2804764624 date "2018-09-10" @default.
• W2804764624 modified "2023-10-14" @default.
• W2804764624 title "Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials" @default.
• W2804764624 cites W2019607817 @default.
• W2804764624 cites W2050249255 @default.
• W2804764624 cites W2099530756 @default.
• W2804764624 cites W2116478428 @default.
• W2804764624 cites W2133185107 @default.
• W2804764624 cites W2147038864 @default.
• W2804764624 cites W2151116840 @default.
• W2804764624 cites W2208535430 @default.
• W2804764624 cites W2290992546 @default.
• W2804764624 cites W2295354328 @default.
• W2804764624 cites W2340678971 @default.
• W2804764624 cites W2345320779 @default.
• W2804764624 cites W2437027409 @default.
• W2804764624 cites W2482427906 @default.
• W2804764624 cites W2492450141 @default.
• W2804764624 cites W2492871464 @default.
• W2804764624 cites W2528370542 @default.
• W2804764624 cites W2533300620 @default.
• W2804764624 cites W2539075538 @default.
• W2804764624 cites W2551769647 @default.
• W2804764624 cites W2564253351 @default.
• W2804764624 cites W2581996620 @default.
• W2804764624 cites W2586673947 @default.
• W2804764624 cites W2610816290 @default.
• W2804764624 cites W2624310346 @default.
• W2804764624 cites W2767072667 @default.
• W2804764624 cites W2768071425 @default.
• W2804764624 cites W2776537462 @default.
• W2804764624 doi "https://doi.org/10.1200/jco.2017.77.5841" @default.
• W2804764624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29768119" @default.
• W2804764624 hasPublicationYear "2018" @default.
• W2804764624 type Work @default.
• W2804764624 sameAs 2804764624 @default.
• W2804764624 citedByCount "113" @default.
• W2804764624 countsByYear W28047646242018 @default.
• W2804764624 countsByYear W28047646242019 @default.
• W2804764624 countsByYear W28047646242020 @default.
• W2804764624 countsByYear W28047646242021 @default.
• W2804764624 countsByYear W28047646242022 @default.
• W2804764624 countsByYear W28047646242023 @default.
• W2804764624 crossrefType "journal-article" @default.
• W2804764624 hasAuthorship W2804764624A5003670561 @default.
• W2804764624 hasAuthorship W2804764624A5007762760 @default.
• W2804764624 hasAuthorship W2804764624A5008594172 @default.
• W2804764624 hasAuthorship W2804764624A5012226414 @default.
• W2804764624 hasAuthorship W2804764624A5014132939 @default.
• W2804764624 hasAuthorship W2804764624A5016978421 @default.
• W2804764624 hasAuthorship W2804764624A5036466135 @default.
• W2804764624 hasAuthorship W2804764624A5038912570 @default.
• W2804764624 hasAuthorship W2804764624A5041640815 @default.
• W2804764624 hasAuthorship W2804764624A5043983803 @default.
• W2804764624 hasAuthorship W2804764624A5055082049 @default.
• W2804764624 hasAuthorship W2804764624A5070967174 @default.
• W2804764624 hasAuthorship W2804764624A5071783009 @default.
• W2804764624 hasAuthorship W2804764624A5073284312 @default.
• W2804764624 hasAuthorship W2804764624A5077797768 @default.
• W2804764624 hasAuthorship W2804764624A5080311196 @default.
• W2804764624 hasAuthorship W2804764624A5082517668 @default.
• W2804764624 hasAuthorship W2804764624A5090256464 @default.
• W2804764624 hasConcept C117643217 @default.
• W2804764624 hasConcept C121608353 @default.
• W2804764624 hasConcept C126322002 @default.
• W2804764624 hasConcept C143998085 @default.
• W2804764624 hasConcept C2776232967 @default.
• W2804764624 hasConcept C2776256026 @default.
• W2804764624 hasConcept C2778164965 @default.
• W2804764624 hasConcept C2778347629 @default.
• W2804764624 hasConcept C2779013556 @default.
• W2804764624 hasConcept C2779422266 @default.
• W2804764624 hasConcept C31760486 @default.
• W2804764624 hasConcept C535046627 @default.
• W2804764624 hasConcept C71924100 @default.
• W2804764624 hasConcept C90924648 @default.
• W2804764624 hasConceptScore W2804764624C117643217 @default.
• W2804764624 hasConceptScore W2804764624C121608353 @default.

• next